Welcome to our dedicated page for Stevanato Group S.p.A. news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S.p.A. stock.
Stevanato Group S.p.A., founded in 1949, is a leader in creating systems, processes, and services that ensure the integrity of parenteral medicines. The company operates through two main divisions:
- Pharmaceutical Systems (Ompi and Balda brands): Specializes in ready-to-use glass containers and bulk primary packaging such as syringes, cartridges, vials, and ampoules. Additionally, it provides high-quality, high-precision plastic solutions for diagnostic, pharmaceutical, and medical device applications.
- Engineering Systems (Spami, Optrel, Innoscan, and SVM brands): Focuses on glass forming technology, inspection systems, assembly, packaging machines, and serialization solutions for the pharmaceutical industry.
These divisions work in close synchronization, featuring daily exchanges that ensure the Stevanato Group maintains complete control over the entire production process, from sourcing the finest raw materials to providing exceptional after-sales customer service.
The group's commitment extends beyond manufacturing; through its SGLab, the Stevanato Group offers analytical and testing services that support pharmaceutical companies in ensuring the safety, efficacy, and integrity of their products.
Stevanato Group addresses customer needs across the entire drug life cycle, including development, clinical, and commercial stages, offering an integrated, end-to-end portfolio of products, processes, and services. The company operates in two segments: Biopharmaceutical and Diagnostic Solutions, which generates key revenue and encompasses products and services for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables; and Engineering.
Geographically, the company derives the majority of its revenue from Europe, the Middle East, and Africa, positioning itself as a significant player in the global pharmaceutical, biotechnology, and life sciences industries.
Stevanato Group (NYSE: STVN) reported strong financial results for Q4 and FY 2022 and provided guidance for FY 2023. Q4 revenue rose 26% to €292.1 million, while FY 2022 revenue increased 17% to €983.7 million. Adjusted diluted EPS for Q4 were €0.19, and for FY 2022, €0.56. The company anticipates FY 2023 revenue between €1.085 billion and €1.115 billion and adjusted EPS of €0.58 to €0.62. Committed backlog grew 9% YoY to €957 million. Positive momentum was noted in high value solutions, accounting for 30% of revenue, with increased capital investments planned in the U.S. to meet demand.
Stevanato Group (NYSE: STVN) will release its fourth quarter and fiscal year 2022 financial results on March 2, 2023, at 6:30 a.m. ET. A conference call and webcast will follow at 8:30 a.m. ET, featuring a slide presentation available on the company’s Investor Relations site. Participants are encouraged to pre-register for expedited access. Dial-in options include +39 02 802 09 11 (Italy), +44 1 212 818004 (UK), and +1 718 705 8796 (USA). A replay of the webcast will be accessible for three months post-event, further enhancing transparency regarding the company’s performance.
Stevanato Group (NYSE: STVN), a global leader in drug containment, has announced a collaboration with Transcoject GmbH to introduce cyclic olefin polymer (COP) and cyclic olefin copolymer (COC) pre-fillable syringes (PFS). This new offering will enhance Stevanato’s existing glass PFS portfolio, enabling greater customization for clients across various applications, including sensitive biologics and mRNA vaccines. The partnership aims to leverage each company's expertise to provide a broad range of format options and increase operational efficiency. The new products will be introduced at the Pharmapack Europe conference in Paris on February 1-2, 2023.
Stevanato Group (NYSE: STVN) announced its participation in the Jefferies London Healthcare Conference scheduled for November 17, 2022, at 12:55 p.m. (GMT). The company, a global leader in drug containment, drug delivery, and diagnostic solutions, will provide a webcast available on its Investors section of the website. Founded in 1949, Stevanato Group supports the pharmaceutical and biotechnology sectors with a comprehensive portfolio of products and services throughout the drug life cycle.
Stevanato Group (NYSE: STVN) reported a strong third quarter of 2022 with a 14% revenue increase to €245.3 million. High-value solutions contributed 30% of total revenue, reflecting a growing shift in focus. The adjusted diluted EPS remained stable at €0.14, with an adjusted EBITDA of €65.8 million and a margin of 26.8%. A notable 21% backlog increase to approximately €1.01 billion underscores strong future demand. The company raised its 2022 guidance, citing favorable currency effects amidst ongoing inflationary pressures.
Stevanato Group has partnered with Gerresheimer AG to launch the EZ-fill Smart™, a new Ready-To-Use (RTU) vial platform. This innovation aims to enhance drug packaging quality, reduce total cost of ownership (TCO), and decrease lead times. Key features include increased automation, no glass-to-glass contact, and an environmentally friendly sterilization method. The platform is set for commercial availability in early 2024. The collaboration responds to a growing demand for RTU vials, positioning itself as the next industry standard in pharmaceutical packaging.
Stevanato Group (NYSE: STVN) has announced a non-exclusive agreement with DWK Life Sciences to distribute its EZ-fill® Ready-to-Use (RTU) solutions. This collaboration aims to enhance the distribution of EZ-fill® products, which include vials and cartridges specifically designed for pharmaceutical use. The EZ-fill® technology has been widely adopted, with over 250 installations in the last 12 years, ensuring quality improvements and reduced costs. The partnership is expected to leverage DWK’s extensive laboratory network to expand Stevanato's market reach.
Stevanato Group S.p.A (NYSE: STVN) will release its third-quarter 2022 financial results on November 8, 2022, at 6:30 a.m. (ET). The company will host a conference call and webcast to discuss these results at 8:30 a.m. (ET) on the same day, which will include a slide presentation available on its Investor Relations webpage.
Participants can pre-register for immediate access, while those unable to do so may dial in directly. The archived webcast will be accessible for three months post-event.
Bexson Biomedical and Stevanato Group have been jointly awarded the PDA's 2022 Drug Delivery Innovation Partnership Award for their collaboration on the On Body Delivery System (OBDS). This recognition highlights their innovative work in optimizing drug delivery solutions for non-opioid pain management, particularly with Bexson's SEVALENT™ formulation technology. The award was presented at the PDA conference in Palm Springs, CA on October 18, 2022. Bexson’s lead therapy, BB106, targets a $36 billion market.
FAQ
What is the current stock price of Stevanato Group S.p.A. (STVN)?
What is the market cap of Stevanato Group S.p.A. (STVN)?
What does Stevanato Group S.p.A. specialize in?
What are the main divisions of Stevanato Group?
What brands fall under Stevanato's Pharmaceutical Systems division?
What services does the Engineering Systems division provide?
What is the role of SGLab in Stevanato Group?
Which industries does Stevanato Group serve?
From which regions does Stevanato Group derive most of its revenue?
How does Stevanato Group support the drug life cycle?
What kind of packaging solutions does Stevanato Group offer?
How long has Stevanato Group been in operation?
